POLY MEDICURE
|
POLY MEDICURE Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 26.91 | 18.69 | 15.28 | 14.17 | 10.86 |
| CEPS(Rs) | 33.57 | 24.64 | 20.90 | 19.13 | 15.46 |
| DPS(Rs) | 3.00 | 3.00 | 2.50 | 2.50 | 2.00 |
| Book NAV/Share(Rs) | 152.82 | 129.17 | 113.24 | 100.62 | 49.26 |
| Tax Rate(%) | 24.98 | 24.51 | 24.96 | 24.54 | 23.74 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 26.10 | 23.88 | 23.19 | 27.39 | 24.06 |
| EBIT Margin(%) | 25.91 | 22.18 | 21.72 | 24.13 | 21.18 |
| Pre Tax Margin(%) | 24.93 | 21.21 | 21.05 | 22.78 | 18.21 |
| PAT Margin (%) | 18.70 | 16.01 | 15.80 | 17.19 | 13.89 |
| Cash Profit Margin (%) | 23.33 | 21.12 | 21.62 | 23.20 | 19.76 |
| Performance Ratios | |||||
| ROA(%) | 14.48 | 11.90 | 11.08 | 13.15 | 12.95 |
| ROE(%) | 19.09 | 15.42 | 14.29 | 19.42 | 23.51 |
| ROCE(%) | 23.63 | 19.10 | 17.42 | 21.96 | 24.80 |
| Asset Turnover(x) | 0.77 | 0.74 | 0.70 | 0.76 | 0.93 |
| Sales/Fixed Asset(x) | 1.19 | 1.22 | 1.22 | 1.21 | 1.25 |
| Working Capital/Sales(x) | 2.82 | 2.18 | 1.67 | 1.48 | 5.54 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.84 | 0.82 | 0.82 | 0.83 | 0.80 |
| Receivable days | 66.78 | 72.05 | 71.34 | 65.34 | 67.54 |
| Inventory Days | 56.78 | 61.45 | 58.03 | 55.09 | 51.78 |
| Payable days | 87.19 | 102.88 | 99.52 | 112.43 | 130.86 |
| Valuation Parameters | |||||
| PER(x) | 59.04 | 51.01 | 62.11 | 57.69 | 21.68 |
| PCE(x) | 47.33 | 38.67 | 45.39 | 42.74 | 15.24 |
| Price/Book(x) | 10.40 | 7.38 | 8.38 | 8.13 | 4.78 |
| Yield(%) | 0.19 | 0.31 | 0.26 | 0.31 | 0.85 |
| EV/Net Sales(x) | 11.10 | 8.17 | 9.98 | 10.10 | 3.28 |
| EV/Core EBITDA(x) | 36.43 | 30.02 | 36.41 | 33.82 | 12.22 |
| EV/EBIT(x) | 42.68 | 36.70 | 45.72 | 41.66 | 15.43 |
| EV/CE(x) | 9.31 | 6.57 | 6.69 | 6.27 | 2.82 |
| M Cap / Sales | 11.08 | 8.20 | 9.86 | 9.97 | 3.03 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 23.36 | 20.82 | 17.37 | 14.44 | 12.51 |
| Core EBITDA Growth(%) | 38.09 | 20.04 | 7.67 | 27.26 | 23.29 |
| EBIT Growth(%) | 44.08 | 23.31 | 5.62 | 30.43 | 28.45 |
| PAT Growth(%) | 44.05 | 22.37 | 7.82 | 41.72 | 46.60 |
| EPS Growth(%) | 44.01 | 22.32 | 7.80 | 30.43 | 46.59 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.12 | 0.12 | 0.12 | 0.14 | 0.47 |
| Current Ratio(x) | 2.15 | 2.46 | 3.46 | 3.48 | 1.55 |
| Quick Ratio(x) | 1.63 | 1.87 | 2.71 | 2.89 | 1.06 |
| Interest Cover(x) | 26.38 | 22.87 | 32.68 | 17.92 | 7.14 |
| Total Debt/Mcap(x) | 0.01 | 0.02 | 0.01 | 0.02 | 0.10 |
Compare Financial Ratios of peers of POLY MEDICURE
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| POLY MEDICURE | ₹19,986.5 Cr | -0.6% | -11% | 3.2% | Stock Analytics | |
| NURECA | ₹238.2 Cr | 0.7% | -16% | -10.9% | Stock Analytics | |
POLY MEDICURE Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| POLY MEDICURE | -0.6% |
-11% |
3.2% |
| SENSEX | -0.5% |
-3.1% |
1.4% |
You may also like the below Video Courses
